145 patients with acute or subacute deep vein thrombosis confirmed by phlebography were treated with streptokinase. During the same period 42 patients considered unfit for thrombolytic therapy were treated with herapin and oral anticoagulants. The results, assessed by repeat phlebography, in 93 of the patients treated with streptokinase were compared with those in the 42 patients treated with heparin. The age, sex, and severity of occlusion were roughly similar in both groups. Streptokinase treatment was successful in 420,, partially successful in 25%, and unsuccessful in 32% of the 93 patients compared with none, 10%, and 880/ respectively in the 42 patients treated with heparin.
Introduction
Early complete reopening of deep veins of the legs after 
Patients and Methods
Only patients with acute or subacute deep vein thrombosis confirmed by phlebography were considered for study. Those Streptokinase in 5% glucose solution for intravenous infusion was prepared twice daily to avoid loss of activity. The initial dose, given through a catheter in a cubital vein and injected slowly over 15-30 minutes in 20-ml glucose solution, was calculated according to the tolerance (see under Laboratory Tests) and plasma volume. The maintenance dose, infused at a rate of 30 ml/h, was two-thirds of the initial dose but did not exceed 100 000 U streptokinasetlh-'). The maintenance dose had sometimes to be modified when the lytic activity was inadequate as judged by fibrinogen concentration and euglobulin lysis time. In cases in which, after an initial rapid fall, the plasma fibrinogen level rose to over 0-8 g/l (80 mg/100 ml) heparin 15 000 to 20 000 U/24 h was given in addition while the dose of streptokinase was reduced to enhance the lytic activity since in nearly all cases an excess of streptokinase bound and inhibited either plasminogen or plasmin. The heparin infusion was continued so long as the plasma fibrinogen level remained over 0-8 g/l. To guard against possible allergic reactions prednisolone was given before the initial dose of streptokinase when this was 200 000 U or more. Prednisolone was also given in cases of allergic reaction during therapy.
Most patients were treated in the intensive care unit under constant supervision. Bleeding, especially at puncture sites, was carefully watched for and urine and faeces were inspected macroscopically for blood and the urine tested with Haemocombistix.
After stopping the streptokinase infusion heparin 10000-20000 U/h and oral anticoagulants were given when the plasma fibrinogen level reached 0-8 g/l. The maintenance dose was adjusted according to the thrombin time.
HEPARIN TREATMENT
Patients unsuitable for thrombolytic treatment were given an initial dose of heparin 5000 U followed by an infusion of 25 000 U/24 h. Further dosage was adjusted according to the thrombin time. Oral anticoagulation was started at the same time as heparin.
LABORATORY TESTS
The streptokinase tolerance, determined by the method of Fischbacher (1961) , was defined as the number of streptokinase units required to lyse completely in 10 minutes at 37°C a clot obtained by recalcification of 1 ml of the patient's plasma. This number multiplied by the approximate plasma volume of the patient gave the initial dose of streptokinase.
The fibrinogen concentration and the inhibitory effect of the circulating fibrinogen or fibrin split products were assayed simultaneously by the method of Clauss (1957) . The coagulation factors II, VII (Koller et al., 1951) , and X (Bachmann et al., 1958) were assayed by previously described methods. Quick prothrombin times under heparin infusion were measured by the method of Seiler et al. (1970) .
The euglobulin lysis time was measured on euglobulin precipitated at pH 5-1-5-2 by acetic acid in distilled water and clotted by thrombin.
The thrombin time was measured, firstly, with a dilute thrombin solution (3-4 National Institutes of Health units/ml), giving a clotting time of [13] [14] [15] [16] seconds with a normal plasma, and, secondly, with a concentrated solution (33 N.I.H.U/ml). Adequate heparinization gave a thrombin time of over two minutes with the diluted solution and of four to eight seconds with the concentrated one.
Results
The results of treatment were evaluated independently by an angioradiologist, an angiologist, and an expert in coagulation, BRITISH MEDICAL JOURNAL 1 MARCH 1975 who studied the phlebograms taken before and at a mean (± S.E. of mean) of 5-8 + 2-5 days after the beginning of treatment. Treatment was rated (a) successfu! if the occluded veins were reopened along the;r whole length or at the point of strategic importance for the venous return-that is, the confluence of the superficial and the deep femoral veins and the great saphenous vein; (b) partially successful if reopening was incomplete; (c) unsuccessful if the phlebogram was unchanged; and (d) adverse if the occlusion had extended further. The ratings for thrombolytic and heparin are compared in table III. recommended standard initial streptokinase dose of 250 000 U streptokinase. Thrombin times, plasma fibrinogen concentrations, and euglobulin lysis times were measured during treatment. Neither the euglobulin lysis nor the thrombin times bore any relation to the outcome. Fibrinogen levels, on the other hand, were lower in patients in whom treatment was successful, nearly all being below 0 8 g/l (table VII). Treatment was never successful in patients whose fibrinogen level remained above 0-8 g/l after the first 48 hours of therapy. For that reason patients treated during the later part of the period under review who had fibrinogen levels of this order were always given heparin in addition to streptokinase. In the 42 patients treated with only heparin and oral anticoagulants the average interval between the start of treatment and the second control phlebogram was 6-7 ± 3-4 days. Treatment was in no case successful, but in four it was partially so. The phlebogram remained unchanged in 37 cases and showed an additional occlusion in one case (table III) . Heparinization was sufficient in all but 10 (24%) patients. In these the thrombin times were less than 60 seconds in more than two-thirds of the daily tests. The smallest daily dose of heparin was 20 000 IU.
SIDE EFFECTS
The incidence of pulmonary embolism was no greater during thrombolytic treatment than during heparinization ( at the infusion site was common with streptokinase and rare with heparin. Two patients had no control phlebogram after streptokinase treatment because they died-one of pulmonary embolism, the other of paradoxical embolism.
Discussion
Our finding that thrombolysis with streptokinase totally or partially clears occluded veins in 67%// of cases compared with 10%' of heparin-treated patients corresponds with those of others in studies of fewer patients (Browse et al., 1968; Kakkar et al., 1969 a; Robertson et al., 1970; Jacobsen, 1973 Schmitt (1975) , loose thrombi are more recent than adherent ones a good prognosis can never be made on the evidence of the phlebogram. It can merely be established that proximal veins, important for venous return, are more often reopened than distal ones, possibly because the occlusions are usually more recent. Though the age of the thrombus is important it is less so than was at first thought. Streptokinase treatment used to be reserved for acute thromboses. Such a limitation is unjustifiable since it is not certain that the valves suffer permanent damage after several days of occlusion, as postulated by Kakkar et al. (1969 b) . Only a follow-up of cases will show whether a relatively late reopening of the veins can prevent subsequent chronic venous insufficiency.
Rethrombosis, observed by others (Dhall et al., 1973; , occurred on only one of our cases, probably because the individual dosage of streptokinase made it possible to maintain the fibrinogen at a constantly low level. We prefer a dosage based on the tolerance test and laboratory assays because, firstly, for the same lytic action the dose is usually smaller and thus more economical (and also possibly reducing the risk of side effects), and, secondly, the fibrinolytic action can be varied according to the laboratory findings. The latter is particularly important. In the past we had no criteria to guide treatment. During the course of this study we found that successful thrombolysis was related to the fibrinogen level, and that treatment was unsuccessful when plasma fibrinogen was above 0-8 g/l (Duckert et al., 1974) . When the plasma fibrinogen could not be reduced below this level heparin was given in addition. The required degree of anticoagulation was achieved and in some cases the fibrinolytic treatment became successful.
